Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11078)	3/28/2017 12:55:44 PM
From: scaram(o)uche	1 Recommendation Recommended By Biotech Jim Read Replies (3) \| Respond to of 12215

"Sufficient receptor occupancy"?? Sounds familiar...... Message 30562788 Over the years at S.I., we've had some great calls, sufficiently researched. Probably fifty, give or take. Rare, these days. Together with your subsequent post to the valuation thread, GREAT CALL Jim. Can't thank you enough for bringing it here. Best! Rick

To: tuck who wrote (11078)	5/4/2017 9:16:21 PM
From: tuck	Respond to of 12215

Cara 1Q CC notes (some of this already known, perhaps, and is given as confirmation): End of P2 FDA meeting for UP likely in third quarter. Expect two 12 week P3 trials for OA, plus one open label safety trial of 52 weeks. Not likely to start until 2018. The raise is in part to fund an expanded pruritus program. Beyond HD, that program would look at non HD CKD, chronic liver disease, atopic dermatitis, and related diseases. The latter, especially, is also a big population/market. All these latter indications would likely be addressed by oral formulations. Power analysis for IV pain. Coming in June. DMC will unblind but will only tell the company if they have sufficient power at 125 patients per arm, or if they need to enroll more (up to 150; beyond that would need approval from FDA) or drop an arm, etc. Secondary endpoint nausea and vomiting, opioid usage tertiary. Stoppage for efficacy is also a possibility, but management downplays the likelihood of that. Company wants to retain US rights to all programs, but would partner ex-US. Thinks they can get reimbursement from CMS without being in the bundle, as there are no alternatives. Cites the precedent of Amgen's calcimimetic, which is a similar situation. Welcome comments from anyone else who listened. Currently holding a pretty substantial sold put position, mostly May 15s and a few 17.5s. Also some shares in the IRA. Feeling fairly comfortable with it, in spite of the post raise weakness. Cheers, Tuck